Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
15 oct. 2024 16h05 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that its Series B Preferred Stock investors, Ampersand...
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
04 nov. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR® PARSIPPANY, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the...
Interpace Named to ‘Most Admired Companies’ List
15 oct. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The...
Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference
18 sept. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming...
Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
06 sept. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming 21st...
Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update
13 août 2019 08h15 HE
|
Interpace Diagnostics Group, Inc.
Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased Conference Call and...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
06 mai 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, May 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of...
Interpace Diagnostics Announces Further Expansion of Thyroid Business
22 janv. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Interpace Only Provider Validated to Offer MDx Tests on Three Distinct Platforms PARSIPPANY, NJ, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it...
Interpace Announces Notice of Allowance from U.S. Patent and Trademark Office Covering BarreGEN®
17 déc. 2018 06h50 HE
|
Interpace Diagnostics Group, Inc.
BarreGEN® is Interpace’s Lead Molecular Diagnostic Pipeline Product for Barrett’s Esophagus Parsippany, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace”)...
Interpace Diagnostics CEO Provides Corporate Update
10 oct. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief...